Tekla Capital Management LLC cut its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 13.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 932,948 shares of the company’s stock after selling 150,895 shares during the quarter. Tekla Capital Management LLC owned approximately 0.09% of Teva Pharmaceutical Industries worth $20,096,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the business. Bridgewater Associates LP boosted its position in Teva Pharmaceutical Industries by 11.3% during the 3rd quarter. Bridgewater Associates LP now owns 23,600 shares of the company’s stock worth $508,000 after acquiring an additional 2,400 shares during the period. Standard Life Aberdeen plc boosted its position in Teva Pharmaceutical Industries by 9.1% during the 3rd quarter. Standard Life Aberdeen plc now owns 75,392 shares of the company’s stock worth $1,624,000 after acquiring an additional 6,292 shares during the period. AMP Capital Investors Ltd boosted its position in Teva Pharmaceutical Industries by 7.1% during the 3rd quarter. AMP Capital Investors Ltd now owns 219,630 shares of the company’s stock worth $4,666,000 after acquiring an additional 14,468 shares during the period. Blair William & Co. IL boosted its position in Teva Pharmaceutical Industries by 62.7% during the 3rd quarter. Blair William & Co. IL now owns 96,565 shares of the company’s stock worth $2,080,000 after acquiring an additional 37,215 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Teva Pharmaceutical Industries by 3.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,980,200 shares of the company’s stock worth $42,654,000 after acquiring an additional 72,875 shares during the period. Institutional investors own 61.66% of the company’s stock.
Shares of Teva Pharmaceutical Industries stock traded up $0.41 on Monday, reaching $21.96. 2,155,398 shares of the company were exchanged, compared to its average volume of 9,038,804. The firm has a market capitalization of $21.90 billion, a PE ratio of 5.59, a price-to-earnings-growth ratio of 6.49 and a beta of 0.74. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $14.05 and a fifty-two week high of $25.96. The company has a quick ratio of 0.61, a current ratio of 0.94 and a debt-to-equity ratio of 1.75.
In other Teva Pharmaceutical Industries news, insider Deborah A. Griffin sold 2,376 shares of the business’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total value of $56,334.96. Following the transaction, the insider now owns 2,376 shares in the company, valued at $56,334.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Richard Daniell sold 2,488 shares of the business’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the transaction, the vice president now owns 2,488 shares in the company, valued at approximately $58,940.72. The disclosure for this sale can be found here. Insiders have sold 6,531 shares of company stock worth $152,749 over the last three months. 0.43% of the stock is owned by insiders.
A number of analysts have recently commented on TEVA shares. BTIG Research raised Teva Pharmaceutical Industries from a “sell” rating to a “neutral” rating in a research note on Monday, September 17th. Wells Fargo & Co set a $23.00 price objective on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Wednesday, October 17th. CIBC reissued a “market perform” rating on shares of Teva Pharmaceutical Industries in a research note on Friday, September 21st. Credit Suisse Group set a $26.00 price objective on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Sunday, October 14th. Finally, Goldman Sachs Group raised Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 price objective on the stock in a research note on Monday, October 1st. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $22.08.
WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2018/12/03/tekla-capital-management-llc-has-20-10-million-holdings-in-teva-pharmaceutical-industries-ltd-teva.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
See Also: Terms to Better Understand Call Options
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.